Apoptosis in the Development and Treatment of Laryngeal Cancer: Role of p53, Bcl-2 and Clusterin

  • Maximino Redondo
  • Rafael Fùnez
  • Francisco Esteban


In cancer, the balance between proliferation and programmed cell death is disturbed, and defects in apoptotic pathways allow cells with genetic abnormalities to survive. Alterations in apoptotic pathways may result in resistance to drugs and radiation. Such alterations might serve as predictors of chemotherapy- and radiotherapy-sensitivity and, most importantly, as new treatment targets. The proteins p53, bcl-2 and clusterin influence the apoptotic activity of the cells. In this report we describe the distribution and possible functional significance of these proteins in squamous cell carcinoma of the larynx. Their implications in carcinogenesis and progression make these genes worthy of investigation.


Laryngeal cancer p53 bcl-2 Clusterin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alsner J, Sorensen SB, Overgaard J (2001) TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 59:179–185PubMedCrossRefGoogle Scholar
  2. Awwad S, Jaros E, Somes J, Lunec J (1996) P53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys 34:323–332PubMedGoogle Scholar
  3. Barnes L, Gnepp DR (2000) Diseases of the larynx, hypopharynx and esophagus. In: Barnes L (ed) Surgical pathology of the head and neck. Decker: New Cork, 1985, pp 293–315Google Scholar
  4. Brachman DA, Beckett M, Haraf D, Graves D, Vokes E, Weichselbaum RR (1993) p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 53:3667–3669PubMedGoogle Scholar
  5. Cataruzza MS, Maissoneuve P, Boyle P (1996). Epidemiology of laryngeal cancer. Eur J Cancer B Oral Oncol 32B:293–305CrossRefGoogle Scholar
  6. Cervellera M, Raschella G, Santilli G, Tanno B, Ventura A, Mancini C, Sevignani C, Calabretta B, Sala A (2000) Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem 275:21055–21060PubMedCrossRefGoogle Scholar
  7. Chen X, Halberg RB, Ehrhardt WM, Torrealba J, Dobe WF (2003) Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci USA 100:9530–9535PubMedCrossRefGoogle Scholar
  8. Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ (2004) Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res 64:7412–7419PubMedCrossRefGoogle Scholar
  9. Chi KN, Gleave ME (2004) Antisense approaches in prostate cancer. Expert Opin Biol Ther 4:927–936PubMedCrossRefGoogle Scholar
  10. Condon LT, Ashman JN, Ell SR Stafford ND, Greenman J, Cawkwell L (2002) Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance. Int J Cancer 100:472–475PubMedCrossRefGoogle Scholar
  11. Cory S, Huang DC, Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22:8590–8607PubMedCrossRefGoogle Scholar
  12. Chung J, Kwak C, Jin RJ, Lee CH, Lee KH, Lee SE (2004) Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Lett 203:155–161PubMedCrossRefGoogle Scholar
  13. De Rienzo DP, Greenberg SD, Fraire AE (1991) Carcinoma of the larynx. Changing incidence in women. Arch Otolaryngol Head Neck Surg 117:681–684Google Scholar
  14. Field JR, Pavelic MD, Spandidos DA, Stambrook PJ, Jones SA, Gkuckman JL (1993) The role of p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 119:1118–1122PubMedGoogle Scholar
  15. Fink TM, Zimmer M, Tschopp J, Etienne J, Jenne DE, Lichter P (1993) Human clusterin (CLI) maps to 8p21 in proximity to the lipoprotein lipase (LPL) gene. Genomics 16:526–528PubMedCrossRefGoogle Scholar
  16. Fracchiolla NS, Capaccio P, Carboni N, Pagliari AV, Neri A, Ronchett D, Pruner G, Silvotti MG, Pignataro L, Buffa R, Broich G (1999) Immunohistochemical and molecular analysis of bax, bcl-2 and agnor counts as prognostic factors in laryngeal squamous cell carcinomas. Anticancer Res 19:1043–1052PubMedGoogle Scholar
  17. Friedman M, Lim JW, Manders E, Schaffner AD, Kirschenbaum GL, Tanyeri HM, Caldarelli DD, Coon JS (2001) Prognostic significance of bcl.2 and p53 expression in advenced laryngeal squamous cell carcinoma. Head and neck 23:280–285PubMedCrossRefGoogle Scholar
  18. Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfirio B (1999) Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer 84:573–579PubMedCrossRefGoogle Scholar
  19. Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, Pezzella F, Harris AL (1995) Expression of bcl-2 protein predicts efficacy of adyuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1:189–198PubMedGoogle Scholar
  20. Gleave M, Jansen B (2003) Clusterin and IGFBPs as antisense targets in prostate cancer. Ann N Y Acad Sci 1002:95–104PubMedCrossRefGoogle Scholar
  21. Gleave M, Miyake H (2005) Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 23:38–46PubMedCrossRefGoogle Scholar
  22. Harris AL (1990) Mutant p53, the commonest genetic abnormality in human cancer? J Pathol 162:5–6PubMedCrossRefGoogle Scholar
  23. Hussein MR (2005) Alterations of p53 and bcl-2 protein expression in the laryngeal intraepithelial neoplasia. Cancer Biol Ther 4:213–217PubMedGoogle Scholar
  24. Hirvikoski P, Kumpulainen E, Virtaniemi J, Pirinen R, Salmi L, Halonen P, Johansson R, Kosma VM (1999) Enhanced apoptosis correlates with poor survival in patients with laryngeal cancer but not with cell proliferation, bcl-2 or p53 expression. Eur J Cancer 35:231–237PubMedCrossRefGoogle Scholar
  25. Homma A, Furuta Y, Oridate N, Nakano Y, Yagi K, Nagahashi T, Fukuda S, Inuyama Y (2001) Correlation of clinicopathological parameters and biological markers related to apoptosis and proliferative activity with a clinical outcome in squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. Auris Nasus Larynx 28 Suppl:S87–94Google Scholar
  26. Israels LG, Israels LD (1999) Apoptosis. The Oncologist 4:332–339PubMedGoogle Scholar
  27. Jackel MC, Dorudian MA, Marx D, Brinck U, Schauer A, Steiner W (1999) Spontaneous apoptosis in laryngeal squamous cell carcinoma is independent of bcl-2 and bax protein expression. Cancer 85:591–599PubMedCrossRefGoogle Scholar
  28. Jordan-Stark TC, Witte DP, Aronow B, Harmony JAK (1992) Apolipoprotein J: a membrane policeman? Curr Op Lipidol 3:75–85Google Scholar
  29. Karamitopoulou E, Perentes E, Tolnay M, Probst A (1998) Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 29:140–145PubMedCrossRefGoogle Scholar
  30. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311PubMedGoogle Scholar
  31. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597PubMedCrossRefGoogle Scholar
  32. Kirszbaum L, Bozas SE, Walker ID (1992) SP-40-40 a protein involved in the control of the complement pathway possesses a unique array of disulphide bridges. FEBS Lett 297:70–76PubMedCrossRefGoogle Scholar
  33. Klokov D, Criswell T, Leskov KS, Araki S, Mayo L, Boothman DA (2004) IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. Mutat Res 568:97–110PubMedGoogle Scholar
  34. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, Yoo GH, Lee DJ, Forastiere AA, Sidransky D (1996) p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:1580–1586PubMedCrossRefGoogle Scholar
  35. Kokoska MS, Piccirillo JF, El-Mofty SK, Emami B, Haughey BH, Scholnik SB (1996) Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer 78:1693–1700PubMedCrossRefGoogle Scholar
  36. Krajewska M, Krajewski S, Epstein J.I, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC (1996) Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. Am J Pathol 148:1567–1576PubMedGoogle Scholar
  37. Kuropkat C, Venkatesan TK, Caldarelli DD, Panje WR, Hutchinson J, Preisler HD, Coon JS, Werner JA (2002) Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx 29:165–174PubMedCrossRefGoogle Scholar
  38. Lee BJ, Wang SG, Roh HJ, Goh EK, Chon KM, Park DY (2006) Changes in expression of p53, proliferating cell nuclear antigen and bcl-2 in recurrent laryngeal cancer after radiotherapy. J Laryngol Otol 120:579–582PubMedGoogle Scholar
  39. Leith JT (1994) Letter to the editor. Cancer Res 54:5021PubMedGoogle Scholar
  40. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485–495PubMedCrossRefGoogle Scholar
  41. Miyake H, Nelson C, Rennie PS, Gleave ME (2000) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Research 60:2547–2554PubMedGoogle Scholar
  42. Miyashita T, Reed JC (1992) bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407–5411PubMedGoogle Scholar
  43. Nadal A, Cardesa A (2003) Molecular biology of laryngeal squamous cell carcinoma. Virchows Arch 442:1–7PubMedGoogle Scholar
  44. Narayana A, Vaughan AT, Gunaratne S, Kathuria S, Walter SA, Reddy SP (1998) Is p53 an independent prognostic factor in patients with laryngeal carcinoma? Cancer 82:286–291Google Scholar
  45. Narayana A, Vaughan AT, Kathuria S, Fisher SG, Walter SA, Reddy SP (2000) P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. Int J Radiat Oncol Biol Phys 46:21–26PubMedCrossRefGoogle Scholar
  46. Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N (2005) Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Br J Cancer 92:2185–2189PubMedCrossRefGoogle Scholar
  47. Olie RA, Zangemeister-Wittke U (2001) Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential. Drug Resist Update 4:9–15CrossRefGoogle Scholar
  48. Pai HH, Rochon L, Clark B, Black M, Shenouda G (1998) Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int J Radiat Oncol Biol Phys 41:37–42PubMedGoogle Scholar
  49. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827–841PubMedCrossRefGoogle Scholar
  50. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2003) Cancer Incidence in Five Continents, Vol VIII. IARC Press, LyonGoogle Scholar
  51. Pasinetti GM, Johnson SA, ODA T, Rozovsky I, Finch CE (1994) Clusterin (SGP-2): A multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J Comp Neurol 339:387–400PubMedCrossRefGoogle Scholar
  52. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY (1993) bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690–694PubMedCrossRefGoogle Scholar
  53. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG (2004) Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23:2298–304PubMedCrossRefGoogle Scholar
  54. Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil RA, Tetu B (1997) Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 15:1030–1038PubMedGoogle Scholar
  55. Redondo M, Villar E, Torres JE, Tèllez T, Petito CK, Morell M (2000) Overexpression of clusterin in human breast carcinoma. Am J Pathol 157:393–399PubMedGoogle Scholar
  56. Redondo M, Esteban F, Gonzàlez-Moles MA, Delgado-Rodrìguez M, Nevado M, Torres-Muñoz JE, Tellez T, Villar E, Morell M, Petito CK (2006) Expression of the Antiapoptotic Proteins Clusterin and Bcl-2 in Laryngeal Squamous Cell Carcinomas. Tumor Biol 27:195–200CrossRefGoogle Scholar
  57. Redondo M, Tèllez T, Roldan MJ, Garcìa-Aranda M, Serrano A, Hortas ML, Morell M (2007) Anticlusterin treatment of breast cancer cells increases chemotherapy- and tamoxifen-sensitivity and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Breast Cancer Res 9:R86Google Scholar
  58. Rosemberg ME, Silkensen J (1995) Clusterin: Physiologic and pathologic considerations. Int J Cell Biol 27:633–645CrossRefGoogle Scholar
  59. Rudoltz MD, Benammar A, Mohiuddin M (1993) Prognostic factor for local control and survival in T1 squamous cell carcinoma of the glottis. Int J Radiat Oncol Biol Phys 26:.762–772Google Scholar
  60. Schattner EJ (2002) Apoptosis in lymphocytic leukemias and lymphomas. Cancer Invest 20:737–748PubMedCrossRefGoogle Scholar
  61. Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Pötter R, Jansen B (1998) Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 8:197–203PubMedCrossRefGoogle Scholar
  62. Skuse AR (1996) The search for prognostic genetic indicators of cancer recurrence. Int J Radiat Oncol Biol Phys 34:509–510PubMedGoogle Scholar
  63. So A, Sinnemann S, Huntsmann D, Fazli L, Gleave M (2005) Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 4:1837–1849PubMedCrossRefGoogle Scholar
  64. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM, Sensibar JA (1997) Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3:1707–1711PubMedGoogle Scholar
  65. Strasser A, Harris AW, Cory S (1991) bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67:889–999PubMedCrossRefGoogle Scholar
  66. Teixeira C, Reed JC, Pratt MA (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902–3907PubMedGoogle Scholar
  67. Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, Singleton T, Wicha M (2002) Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 112:638–644PubMedCrossRefGoogle Scholar
  68. Trougakos IP and Gonos ES (2002) Clusterin/Apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 34:1430–1448PubMedCrossRefGoogle Scholar
  69. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES (2004) Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64:1834–1842PubMedCrossRefGoogle Scholar
  70. Tsujimoto Y (1989) Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. Oncogene 4:1331–1336PubMedGoogle Scholar
  71. Villar E, Redondo M, Rodrigo I, Garcìa J, Avila E, Matilla A (2001) The clinical significance of bcl-2 expression and apoptosis in primary and metastatic breast carcinomas. Tumor Biol 22:137–145CrossRefGoogle Scholar
  72. Villard JF, Lacombe F, Belloc F, Pellegrin JL, Reiffers J (2001) Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology. Cancer Radiother 5:109–129Google Scholar
  73. Vogelstein B (1990) Cancer, a deadly inheritance. Nature 348:681–682PubMedCrossRefGoogle Scholar
  74. Wallace-Brodeur RR, Lowe SW (1999) Clinical implications of p53 mutations. Cell Molec Life Sci 55:64–75PubMedCrossRefGoogle Scholar
  75. Watling DL, Gown AM, Coltrera MD (1992) Overexpression of p53 in head and neck cancer. Head Neck 14:437–444PubMedCrossRefGoogle Scholar
  76. Wilson GD, Grover R, Richman PI, Daley FM, Saunders MI, Dische S (1996) Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 16:2403–2408PubMedGoogle Scholar
  77. Whisler LC, Wood NB, Caldarelli DD, Hutchinson JC, Panje WR, Friedman M, Preisler HD, Leurgans S, Nowak J, Coon JS (1998) Regulators of proliferation and apoptosis in carcinoma of the larynx. Laryngoscope 108:630–638PubMedCrossRefGoogle Scholar
  78. Xie X, Clausen O, De Angelis P, Boysen M (1999) The prognostic value of spontaneous apoptosis, bax, bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 86:913–920PubMedCrossRefGoogle Scholar
  79. Yuen AP, Lam KY, Choy JT, Ho WK, Wei WI (2001) The clinicopathological significance of bcl-2 expression in the surgical treatment of laryngeal carcinoma Clin Otolaryngol 26:129–133Google Scholar
  80. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME (2001) Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3:360–367PubMedCrossRefGoogle Scholar
  81. Zhan Q, Kontny U, Iglesias M, Alamo I JR, Yu K, Hollander MC, Woodworth CD, Fornace AJ (1999) Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress. Oncogene 18:297–304PubMedCrossRefGoogle Scholar
  82. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY (2005) Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 7:909–915PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Maximino Redondo
    • 1
    • 2
  • Rafael Fùnez
    • 3
    • 2
  • Francisco Esteban
    • 4
    • 5
  1. 1.Department of BiochemistryHospital Costa del Sol
  2. 2.University of MalagaMarbellaSpain
  3. 3.Department of PathologyCIBER Epidemiologia y Salud Publica (CIBERESP), Hospital Costa del SolSpain
  4. 4.Department of OtolaryngologyHospital Virgen del Rocio, Avda.
  5. 5.University of SevillaSevillaSpain

Personalised recommendations